MET Loss Reference Standard | |
| Format | Genomic DNA |
| Description | MET, MET proto-oncogene, receptor tyrosine kinase, is a receptor tyrosine kinase, which activates MAPK, PI3K/AKT, SRC, and STAT pathways to promote cell proliferation, invasion, and angiogenesis (PMID: 22128285). MET mutations, exon 14 skipping mutations (PMID: 31369639), and fusions have been identified in a variety of human cancers (PMID: 28603720), including lung cancer (PMID: 32273721), and MET amplification and/or overexpression has been reported in many solid tumors, including biliary tract cancer (PMID: 32085275), breast cancer (PMID: 31991499, PMID: 31892551, PMID: 32234363), NSCLC (PMID: 31832192), gastric cancer (PMID: 31499745), intrahepatic cholangiocarcinoma (PMID: 32089411), and gallbladder carcinoma (PMID: 31645095). |
| Technical Data | |
| Copy number | 1 |
| Definition | Loss |
| Product Information | |
| Intended Use | Research Use Only |
| Unit Size | 1ug |
| Concentration | Download for COA |
| Purity | Download for COA |
| DNA electrophoresis | Download for COA |
| Sanger sequencing | Download for COA |
| Storage | 4℃ |
| Expiry | 36 months from the date of manufacture |
E-mail：sales@reqbio.com
Add:3rd Floor, No. 6, Lane 222,
Guangdan Road, Pudong New Area,
Shanghai，China
WeChat public account
